Can-Fite Biopharma Says Its Phase 3 Study For Namodenoson For Advanced Liver Cancer Is 31 Recruiting Medical Centers. Namodenoson Has Orphan Drug Status From FDA And European Medicines Agency, And FDA Fast Track Status
Portfolio Pulse from Benzinga Newsdesk
Can-Fite Biopharma announced that its Phase 3 study for Namodenoson, a treatment for advanced liver cancer, is now recruiting at 31 medical centers. Namodenoson has received Orphan Drug status from both the FDA and the European Medicines Agency, as well as FDA Fast Track status. Additionally, a compassionate use program is ongoing in Israel and Romania.
June 05, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite Biopharma's Phase 3 study for Namodenoson in advanced liver cancer is progressing with recruitment at 31 medical centers. The drug's Orphan Drug and Fast Track status from the FDA and EMA, along with ongoing compassionate use programs, could positively impact the stock.
The progression of the Phase 3 study and the regulatory designations (Orphan Drug and Fast Track status) are positive indicators for the potential success of Namodenoson. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100